<PAGE>
Conformed Copy
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 22, 1998
----------------
CYTOGEN CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-02015 22-2322400
--------------- ----------- -------------------
(State or other (Commission (IRS Employer
jurisdiction of File No.) Identification No.)
Incorporation or
Organization)
600 College Road East, CN 5308, Princeton, New Jersey 08540-5308
- -----------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609)987-8200
-------------
<PAGE>
Item 5. Other Events.
-------------
On January 22, 1998, CYTOGEN Corporation issued the attached
press release.
Item 7. Exhibits.
---------
99.1 Press release issued by CYTOGEN Corporation on January 22, 1998
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
CYTOGEN CORPORATION
By /s/ Donald F. Crane, Jr.
------------------------
Name: Donald F. Crane, Jr.
Title: Vice President
General Counsel and Secretary
Date: January 23, 1998
3
EXHIBIT 99.1
CONTACT: Jean Mantuano
Corporate Communications
609-987-8221
NEWS RELEASE
For Immediate Release
CYTOGEN ANNOUNCES MANAGEMENT CHANGES
PRINCETON, NJ, January 22, 1998 -- CYTOGEN Corporation
(NASDAQ:CYTO) announced today that William C. Mills III, a member
of the Company's Board of Directors, has assumed the office of
Chairman of the Board, a position he previously held from January
1995 through May 1996. Mr. Mills is a General Partner of The
Venture Capital Fund of New England. The Company also announced
that John E. Bagalay, Jr., who is also a member of the Board of
Directors, will serve as interim President and Chief Executive
Officer pending conclusion of the Company's search for a new Chief
Executive Officer. Dr. Bagalay will continue as CYTOGEN's interim
Chief Financial Officer. Thomas J. McKearn, M.D., Ph.D. has
relinquished his positions as Chairman, President and Chief
Executive Officer of the Company as had been announced previously,
and is returning to a scientific role in the Company. Dr. McKearn
is assuming responsibilities as President of the Company's Cellcor
operations, with the key assignment of seeking regulatory approval
for Cellcor's Autologous Lymphocyte Therapy (ALT). The Company has
concluded Phase III clinical trials for ALT and plans to submit a
Biologic License Application to the U.S. Food and Drug Administration
(FDA) during the first quarter of 1998.
Mr. Mills stated, "This step represents a continuation of the
Company's evolution, beginning with allocating resources to their
best fit in an environment in which our commercial operations are
beginning to expand. Dr. McKearn's talents are ideally suited to
what we believe is the final step in the FDA review process of ALT.
We believe ALT, if licensed for marketing by the FDA, has the
potential to address unmet medical needs for treatment of life
threatening metastatic renal cell carcinoma."
Dr. Bagalay added, "We will continue to direct our resources toward
aggressive commercialization and profitability. We have good
people, good science and good products at CYTOGEN. With these
resources, we are excited about the challenges and opportunities
for the upcoming year."
The Company also announced that a recruiting firm had been engaged
for the Chief Executive Officer search and stated that the search
for a permanent Chief Financial Officer would await a selection of
a new Chief Executive Officer. No time frame could be given for
the selection process.
Information contained in this press release which is not historical
is forward looking. Actual results may differ and are subject to
risks and uncertainties, including the ability to obtain regulatory
approvals, acceptance in the market of any approved technology, and
other risks reviewed in the Company's filings with the Securities
and Exchange Commission.
###
